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Abstract
Background: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies
characterized by locoregional invasion and distant metastasis. Topoisomerase IIα (topoIIα), located
at chromosome 17q21-22, is considered a major mediator of cell proliferation and DNA
replication. The purpose of this study was to evaluate the expression of topoIIα in various types of
salivary gland tumors and its biological significance.
Methods: The protein expression of topoIIα was evaluated immunohistochemically in formalin-
fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10
pleomorphic adenomas and 10 Warthin's tumors). The primary salivary gland carcinoma specimens
consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7
mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex
pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2
lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous
cell carcinoma. The associations between clinicopathological factors and outcome were analyzed.
Results: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (≥10%)
of topoIIα protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
Expression of topoIIα was more frequently observed in salivary duct carcinoma, carcinoma ex
pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was
associated with advanced stage and shortened survival.
Conclusion: The results of the present study suggest that topoIIα expression is associated with
histologically aggressive subtypes and shortened survival. Furthermore, it may provide useful
prognostic information and suggests the potential efficacy of topoIIα-targeting therapy in patients
with salivary gland carcinoma.
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Background
Salivary gland carcinomas are uncommon neoplasms,
accounting for approximately 5% of those arising in the
head and neck region [1]. These tumors are characterized
by widely varied histological features with heterogeneous
and unpredictable clinical behaviors. In general, these car-
cinomas may be categorized into low grade and high
grade malignancies based on their origin from either the
terminal (intercalated) or the excretory ductal epithelium,
respectively [2]. Biological and clinical classifications have
been dependent on this histogenetic classification, but
they are occasionally diverse even within those categories
[3]. Patients with higher histological grades appear to be
more susceptible to locoregional recurrence and distant
metastasis. However, effective treatment for unresectable
tumors has not been established [4]. Although chemo-
therapy remains the main treatment modality for patients
with advanced disease, the efficacy of systemic chemo-
therapy appears to be limited or controversial in high-
grade salivary gland carcinomas.
Topoisomerase IIα (topoIIα), a nuclear enzyme, has a key
role in DNA replication. Consistent with its major role in
DNA replication, overexpression of topoIIα has been
detected in cells with high proliferation activity [5,6]. The
gene encoding topoIIα is located at chromosome 17q21-
22 and encodes for a 170 kDa protein. Interestingly, this
gene is also in close proximity to the HER2 oncogene,
which encodes for a transmembrane tyrosine kinase
receptor protein and has been shown to be frequently
coamplified in several cancers, including breast cancer [7].
Overexpression of HER2 has been reported in salivary
gland carcinomas of excretory cell origin, including sali-
vary duct and squamous cell carcinomas, but not in those
of intercalated cell origin, including adenoid cystic, acinic
cell, and adenocarcinomas, and it is associated with poor
clinical prognosis in patients with salivary duct carcinoma
[8]. On the other hand, little information is available
about the expression of topoIIα protein in salivary gland
tumors.
TopoIIα is a known cellular target for anticancer agents
such as anthracyclines. Anthracyclines inhibit the activity
of topoIIα by stabilizing DNA cleavage, thus exerting anti-
cancer effects [6]. Previous clinical investigations have
shown that amplification and overexpression of topoIIα
are associated with good response to anthracycline-based
chemotherapy in several cancers, such as breast cancer [9-
11]. Anthracyclines as a single agent or in combination
therapy have shown certain effects in mucoepidermoid
carcinomas and high-grade adenocarcinomas, whereas
they likely have a limited effect in adenoid cystic carcino-
mas [4]. These observations suggest that identifying bio-
logical markers that can predict sensitivity to drugs may
also allow stratification of patients for treatment. The pur-
pose of the present study was to evaluate topoIIα expres-
sion levels in different histological types of salivary gland
tumors and to estimate its potential use as a prognostic
marker or clinical target in the treatment of patients with
salivary gland cancers.
Methods
Tissue samples from surgical cases
Tumor specimens from 54 patients with primary salivary
gland carcinomas who underwent surgery or biopsy
between 1996 and 2007 were retrieved from the Depart-
ment of Pathology, Hirosaki University, and associated
hospitals. Tumor specimens consisted of 17 adenoid
cystic carcinomas, 7 mucoepidermoid carcinomas, 7 ade-
nocarcinomas not otherwise specified, 6 salivary duct car-
cinomas, 3 carcinomas ex pleomorphic adenomas, 3
acinic cell carcinomas, 3 epithelial-myoepithelial carcino-
mas, 2 myoepithelial carcinomas, 2 lymphoepithelial car-
cinomas, and 2 carcinosarcomas. There was only one
sample of squamous cell carcinoma and one of oncocytic
carcinoma. To compare the expression status of benign
tumors, 10 pleomorphic adenomas and 10 Warthin's
tumors were also selected (Table 1). All samples were
fixed in a 10% formaldehyde solution and embedded in
paraffin. Diagnosis and histological classification were
based on the World Health Organization Classification
(version 2005) [12]. Informed consents from patients
were obtained for the use of resected tumor specimens.
The study design and procedure involving the human tis-
sue sampling collection were approved by the ethical
board of Hirosaki University.
Immunohistochemistry
For immunohistochemistry, 4-μm-thick sections were
deparaffinized in xylene and rinsed in ethanol. For anti-
gen retrieval, the sections were heated for 15 min at
121°C in Target Retrieval Solution (DakoCytomation,
Glostrup, Denmark) by autoclaving. Endogenous peroxi-
dase was blocked by incubation in methanol with 0.3%
H2O2 for 15 min, followed by rinsing in PBS containing
0.1% Tween 20. Immunohistochemical staining was per-
formed with the EnVision™+ System Kit (DakoCytoma-
tion) according to the manufacturer's protocol. After
treatment with blocking solution, the slides were incu-
bated with the monoclonal primary antibody against
topoisomerase IIα (clone Ki-S1; DakoCytomation; dilu-
tion 1:100) overnight at 4°C. The slides were then incu-
bated at room temperature for 30 min with a dextran
polymer conjugated with horseradish peroxidase enzyme
and secondary anti-mouse antibody. The reaction prod-
ucts were detected with 3,3'-diaminobenzidine tetrahy-
drochloride as the chromogen, and the slides were
counterstained with hematoxylin. The number of positive
cells in 1000 tumor cells within 4–6 microscopic fields at
×200 magnification was counted and semiquantitativelyBMC Cancer 2009, 9:72 http://www.biomedcentral.com/1471-2407/9/72
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graded as follows: 0 (negative, 0% to 9%), 1+ (focal, 10%
to 24%), 2+ (moderate, 25% to 49%), and 3+ (diffuse,
≥50%). Quantitation of positive cells was conducted by 3
independent observers (S.M., H.M. and H.K.), and inter-
observer concordance was over 95%.
Statistical analysis
Statistical analysis was performed using Fisher's exact test
to evaluate significant differences between pairs of find-
ings. The Kaplan-Meier method and the log-rank test were
used for univariate survival analysis. For multivariate sur-
vival analysis, each clinicopathologic parameter was ana-
lyzed using a Cox proportional hazards regression model.
Differences with a P < 0.05 were considered statistically
significant. All statistical examinations were performed
using SPSS 16.0 software package (SPSS Japan, Inc.,
Tokyo, Japan).
Results
Clinical factors
Of the 54 patients with salivary gland carcinomas, 37
(69%) were males and 17 (31%) were females. Their age
ranged from 6 to 84 years (mean, 61.9 years); patients
with mucoepidermoid carcinoma were the youngest
(mean, 51.0 years), and patients with salivary duct carci-
noma were the oldest (mean, 72.8 years). Most tumors
were located in the parotid gland (65%, 35/54), followed
by the minor salivary glands (22%, 12/54) and the sub-
mandibular gland (13%, 7/54). Of the 54 patients, 21
(39%) presented with stage I or II disease, and 33 (61%)
presented with stage III or IV disease. In most cases, the
primary treatment was surgical excision (85%, 46/54).
The mean follow-up time for all 54 patients was 43
months (range, 6 to 133 months). The overall survival
was 55% at 5 years (Fig. 1A). When the survival rate was
compared by histologic type, univariate and multivariate
survival analyses revealed that the group consisting of sal-
ivary duct carcinoma and carcinoma ex pleomorphic ade-
noma had the shortest survival, less than 3 years (Fig. 1B)
(Table 2). In addition, the survival rate of patients with
advanced clinical stages (stage III and IV) was significantly
shorter than that of patients with stages I and II (p =
0.023) (Fig. 1C).
Table 1: TopoIIa expression status in different histologic types
Topo IIα Expression Grade
Histological type 0 1+ 2+ 3+ Total
Benign tumor
Pleomorphic adenoma 10 0 0 0 10
W a r t h i n ' s  t u m o r 1 0 0001 0
Malignant tumor
Adenoid cystic carcinoma 5 7 3 2 17
Adenocarcinoma, 2 0 2 3 7
not otherwise specified
Mucoepidermoid carcinoma 3 2 2 0 7
Salivary duct carcinoma 0 1 0 5 6
Acinic cell carcinoma 2 0 0 1 3
Carcinoma ex pleomorphc adenoma 0 0 0 3 3
Epithelial-myoepithelial carcinoma 2 1 0 0 3
Carcinosarcoma 0 0 1 1 2
Lymphoepithelial carcinoma 1 0 1 0 2
Myoepithelial carcinoma 0 1 0 1 2
Oncocytic carcinoma 1 0 0 0 1
Squamous cell carcinoma 0 0 0 1 1
Table 2: Cox regression analysis for survival
Factors Hazard Ratio (95% confidence interval) p-Value
Age (< 50 vs. > 50) 0.468 (0.100–2.205) 0.337
Gender (male vs. female) 1.403 (0.473–4.159) 0.542
Location (major vs. minor) 0.656 (0.216–1.993) 0.457
Stage (I, II vs. III, IV) 0.424 (0.113–1.592) 0.204
Histological type (SDC+CaPA vs. others) 0.207 (0.056–0.756) 0.017
TopoIIα expression (0, 1+ vs. 2+, 3+) 0.068 (0.018–0.260) < 0.001
SDC: salivary duct carcinoma; CaPA: carcinoma ex pleomorphic adenomaBMC Cancer 2009, 9:72 http://www.biomedcentral.com/1471-2407/9/72
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Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma Figure 1
Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma. Overall survival rate for: (A) total number 
of cases;(B) histological subtype of tumor comparing salivary duct carcinoma (SDC) and carcinoma ex pleomorphic adenoma 
(CaPA) with other types; and (C) each clinical stage.
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TopoIIα expression in benign and malignant salivary gland 
tumors
The immunohistochemical expression of topoIIα was
negative in the epithelial cells of all 20 benign tumors,
including pleomorphic adenoma and Warthin's tumor
(Fig. 2A and 2B), whereas positive expression of topoIIα
protein (≥10%) was found in 38 of 54 malignant tumors
(70%) (p < 0.001) (Table 1). In Warthin's tumors, focal
immunopositivity was detected in germinal centers of
lymphoid stromal cells, but not in epithelial cells (Fig.
2B). In adenoid cystic carcinoma and mucoepidermoid
carcinoma, nuclear staining of topoIIα was positive in 12
cases (71%) and 4 cases (57%), respectively. In adenoid
cystic carcinoma, topoIIα expression seemed to be more
remarkable in solid type than tumors composed of tubu-
lar or cribriform pattern (Fig. 2C and 2D). High expres-
sion (3+) was mainly associated with high-grade
malignant tumors such as salivary duct carcinoma (83%,
5/6), adenocarcinoma not otherwise specified (43%, 3/
7), and carcinoma ex pleomorphic adenoma (100%, 3/3)
(Table 1). In salivary duct carcinoma, the nuclear expres-
sion of topoIIα was evident in both conventional type
with comedonecrosis and microinvasive variant (Fig. 2E
and 2F). All malignant components of the 3 carcinomas
ex pleomorphic adenomas were mainly composed of sal-
ivary duct carcinoma.
Correlation between TopoIIα expression and prognosis in 
malignant salivary gland tumors
In order to evaluate the prognostic factors for salivary
gland carcinomas, multivariate survival analysis using a
Cox proportional hazards regression model was per-
formed, and the expression status of topoIIα protein was
identified as the most significant of several clinicopatho-
logical factors (p < 0.001) (Table 2). The mortality rate of
the low expression group (grade 0 and 1+) was 14.3% (4/
28), while that of the high expression group (grade 2+ and
3+) was 69.2% (18/26). The average survival period as
determined by the Kaplan-Meier method was 114 months
for the low expression group (95% confidence interval:
95–133 months) and 26 months for the high expression
group (95% confidence interval: 16–36 months) (Fig. 3);
the difference in survival between the groups was statisti-
cally significant (p < 0.001).
Correlation between TopoIIα expression and 
clinicopathological parameters
The relationship between topoIIα expression and clinico-
pathological factors is presented in Table 3. TopoIIα over-
expression was frequently seen in patients with advanced
stage disease (P = 0.024).
Relationship between TopoIIα expression and histological 
grade in adenoid cystic carcinoma
Since adenoid cystic carcinoma accounted for the majority
of the tumors, the relationship between topoIIα expres-
sion and the aggressive histological form was evaluated.
The histological grade was determined according to the
criteria of Szanto et al.: Grade 1, tumor with tubular and
cribriform pattern; Grade 2, tumor with a pure cribriform
pattern or mixed with less than 30% solid areas; and
Grade 3, tumor with more than 30% solid areas [3].
Tumors with grades 1 and 2 predominantly showed low
expressions (12/14), whereas all 3 cases with grade 3
tumors demonstrated diffuse and strong expressions
(Table 4), though this difference was not statistically sig-
nificant (p = 1.00).
Discussion
The present results show that topoIIα is differentially
expressed in salivary gland carcinomas and is associated
with aggressive histologic type, advanced disease, and
poor clinical outcome. To the best of our knowledge, this
is the first study to correlate clinical and prognostic fea-
tures with topoIIα expression in various types of salivary
gland tumors. In a multifactorial analysis, topoIIα expres-
sion was more significantly correlated with overall sur-
vival than clinical stage (Table 2). Several studies have
indicated that high expression of topoIIα is considered a
feature of enhanced cellular proliferation [5,6]. It has
been reported that overexpression of topoIIα is associated
with poorer survival rates in several malignancies, includ-
ing head and neck squamous cell carcinoma, glioblast-
oma, and breast cancer [13-15]. The present findings also
support an association between topoIIα expression and
aggressive histological subtypes (salivary duct carcinoma,
carcinoma ex pleomorphic adenoma, adenocarcinoma,
high-grade adenoid cystic carcinoma, and carcinosar-
coma) [16]. Of 9 cases with salivary duct carcinoma and
carcinoma ex pleomorphic adenoma, most (8 cases)
showed diffuse and strong nuclear expressions of topoIIα;
2 cases of carcinosarcoma had high expression of topoIIα.
Carcinosarcoma, which is composed of both malignant
epithelial and malignant mesenchymal components,
occasionally occurs from pleomorphic adenoma [17].
Paradoxically, there was no topoIIα expression in benign
tumors. In this context, overexpression of topoIIα may be
a key event in the malignant transformation of pleomor-
phic adenoma.
Currently, standard chemotherapy regimens for salivary
gland carcinomas have not been established [4]. TopoIIα
is not only known to be a prognostic marker, but it is an
important target for topoisomerase II poisons, such as
anthracycline and epipodophyllotoxin, in several human
cancers. These agents exert an anticancer effect by stabiliz-
ing the cleavage of double-stranded DNA. Previous inves-BMC Cancer 2009, 9:72 http://www.biomedcentral.com/1471-2407/9/72
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Immunohistochemistry for topoIIα in salivary gland tumors Figure 2
Immunohistochemistry for topoIIα in salivary gland tumors. A: Pleomorphic adenoma: few positive nuclear expres-
sions in tumor cells (×100). B: Warthin's tumor: abundant positive expression in lymphoid cells of germinal centers, not in epi-
thelial tumor cells (×100). C: Adenoid cystic carcinoma (Grade 1): low expression in low-grade tubular components (×100). 
D: Adenoid cystic carcinoma (Grade 3): high nuclear expression in high-grade solid areas (×100). E: Salivary duct carcinoma: 
many positive cells in foci with typical comedonecrosis (×100). F: Salivary duct carcinoma: strong and diffuse expression 
observed in the invasive micropapillary variant (×200).BMC Cancer 2009, 9:72 http://www.biomedcentral.com/1471-2407/9/72
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tigations have shown that the sensitivity of topoIIα
inhibitors, such as anthracyclines or epipodophyllotoxin,
is dependent on increased topoIIα expression levels
[18,19]. Coincidentally, the gene encoding topoIIα is
located at chromosome 17q21-22, which is contiguous
with the region encoding HER2. In the field of salivary
gland carcinomas, a previous study has shown that over-
expression of HER2 is more common in salivary gland
carcinomas of excretory cell origin, such as salivary duct
carcinoma, mucoepidermoid carcinoma, and squamous
cell carcinoma [8]. Nguyen et al. [20] also reported a
potential association between HER2 overexpression and
histological aggressiveness in mucoepidermoid carci-
noma. The present data demonstrated that the expression
status of topoIIα might be identical to that of HER2,
showing common expression in cases of de novo salivary
duct carcinoma and in malignant components from carci-
noma ex pleomorphic adenoma. The molecules associ-
ated with amplification of chromosome 17q21-22 may
have important roles as diagnostic and therapeutic targets
in salivary gland carcinomas. This hypothesis is under-
scored by a recent phase II trial of herceptin in salivary
gland cancers overexpressing HER2. A single dose of her-
ceptin (trastuzumab), a monoclonal antibody directed
against HER2 protein, contributed to stabilization of dis-
ease in several cases of salivary duct carcinoma [4,8].
Recently, Prat et al. [21] reported a metastatic salivary duct
carcinoma in which complete response was obtained by
the combination of paclitaxel, carboplatin, and herceptin.
These observations imply that the therapeutic approaches
targeting chromosome17q21-22 region encoding topoi-
somerase IIα and HER2 proteins may benefit patients
with high-grade salivary gland carcinomas.
Adenoid cystic carcinoma is the subtype that has been
most widely investigated in various types of salivary gland
carcinomas. It has been well known that its clinical behav-
ior is dependent on histological grade, with poorer prog-
Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma by topoIIαgrotein expression level (low vs. high) Figure 3
Kaplan-Meier survival analysis of 54 cases with salivary gland carcinoma by topoIIαgrotein expression level 
(low vs. high).
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nosis in the solid type than in the tubular or cribriform
type, and the propensity for perineural invasion is histo-
logically characterized [3]. We previously reported that
low expressions of p16 and E-cadherin were associated
with poor prognosis and aggressive histological type in
adenoid cystic carcinoma [22,23]. In the present study,
high expressions of topoIIα were observed in tumors pre-
dominantly composed of solid areas, though the differ-
ence was not statistically significant due to the small
number of cases. Other major proliferation or anti-apop-
totic markers, such as Ki-67, bcl-2, and cyclin D1, were fre-
quently expressed in adenoid cystic carcinoma, but they
had less of an impact on the discrimination of histological
grade of adenoid cystic carcinoma [24-26]. In this context,
topoIIα may be an excellent marker to evaluate biological
and histological aggressiveness in adenoid cystic carci-
noma, although further evaluation in a large subset of
tumors is needed.
The present study showed a significant association
between topoIIα expression and clinical staging, suggest-
ing that overexpression of topoIIα was associated with
rapid growth of cancer cells and susceptibility to locore-
gional or distant metastasis. High expression of topoIIα is
considered to be a general feature of highly proliferating
cells with rapid cell cycle acceleration [5,6]. Our observa-
tions may be supported by a previous investigation in oral
squamous cell carcinoma, which showed that topoIIα
expression was more significant in cases with lymph node
metastasis than those without lymph node metastasis
[27]. Thus, topoIIα may be a valuable marker for evaluat-
ing the proliferative activity of salivary gland tumor cells.
Conclusion
In conclusion, the present study suggests that topoIIα
expression is an independent prognostic factor for salivary
gland carcinoma, and assessment of topoIIα expression
may be valuable for predicting clinical aggressiveness.
While certain factors, such as clinical stage and his-
topathological grade, play a pivotal role in the manage-
ment of patients with salivary gland carcinoma, high
expression of topoIIα may warrant an intensive modality
of therapy that includes adjuvant chemotherapy targeting
topoIIα protein and radiation. Further investigations are
needed to clarify the significance of topoIIα as a practical
therapeutic target.
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